Clinical Trial Update: Glucose Consumption in MS Using [F-18]FDG-PET [Phase 4]

View source ↗

Summary

Phase 4 clinical trial assessing brain glucose uptake in multiple sclerosis using [18F]FDG-PET imaging; recruitment is currently open.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Fluorodeoxyglucose (FDG) labeled with Fluorine-18 (fluorodeoxyglucose)

Snippet

Sponsor: Brigham and Women's Hospital | Conditions: Multiple Sclerosis | Phase 4 | Status: RECRUITING